Hepatitis C Drugs Market Analysis & Forecast: 2026-2033

The hepatitis C drugs market size is expected to reach US$ 14.02 billion by 2033, from US$ 10.30 billion in 2026, growing at a CAGR of 4.5% during the forecast period. Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it.

Symptoms of hepatitis C include fever, feeling very tired, loss of appetite, nausea and vomiting, abdominal pain, dark urine, pale feces, joint pain, and jaundice (yellowing of the skin or eyes).

Hepatitis c Drugs Market Regional Insights:

• North America is expected to be the largest market for hepatitis C drugs during the forecast period, accounting for over 40.6% of the market share in 2026 The growth of the market in North America is attributed to increasing product launches
• Europe is expected to be the second-largest market for hepatitis C drugs, accounting for over 27.3% of the market share in 2026. The growth of the market in the region is attributed to increasing inorganic strategies by the market players.

• Asia Pacific is expected to be the fastest-growing market for hepatitis C drugs, growing with a CAGR of over 6.2% during the forecast period. The growth of the market in Asia Pacific is attributed to the increasing prevalence of hepatitis C in the region.

Figure 1. Global Hepatitis C Drugs Market Share (%), by Region, 2026

To learn more about this report, Download Free Sample

Analysts’ Views on Global Hepatitis C Drugs Market:

Hepatitis C drugs market is expected to propel over the forecast period due to the increasing prevalence of hepatitis c globally and increasing research and development, and product launches by the market players. Moreover, increasing funding for research and developmental activities is also expected to boost the market growth over the forecast period.

Hepatitis C Drugs Market Drivers:

• Growing Prevalence of Hepatitis C Globally: Increasing prevalence of hepatitis C globally is expected to drive the market growth over the forecast period. For instance, according to the data published by the World Health Organization on July 18, 2026, globally, an estimated 58 billion people have chronic hepatitis c virus infection, with about 1.5 billion new infections occurring per year. There are an estimated 3.2 billion adolescents and children with chronic hepatitis c infections.
• Increasing Government Initiatives: the Ministry of Health & Family Welfare Government of India has initiated the National Viral Hepatitis Control Program, the aim of the program is to combat hepatitis and achieve countrywide elimination of Hepatitis C by 2033.
•  

Hepatitis c drugs market Opportunities:

• Increasing Product Availability in Various Regions: Increasing availability of products globally will increase the yearly revenues of the product, which is expected to propel the market growth over the forecast period. For instance, on July 20, 2026, The Drug Technology Institute (Farmanguinhos) with Oswaldo Cruz Foundation (Fiocruz) signed a technical and scientific cooperation agreement with the Drugs for Neglected Diseases initiative (DNDi) and Pharco Pharmaceuticals in Egypt to request the registration of ravidasvir, a hepatitis C treatment.

Hepatitis C Drugs Market Trends:

• Increasing Partnerships among Market Players: Increasing partnerships among the market players will drive the market growth over the forecast period. For instance, on November 12, 2018, AbbVie, a pharmaceutical company, and the Medicines Patent Pool (MPP) entered into a new, royalty-free licensing agreement to accelerate access to AbbVie’s pan-genotypic hepatitis C virus (HCV) treatment glecaprevir/pibrentasvir (G/P) in 99 low- and middle-income countries and territories.

Hepatitis C drugs market Restraints:

• Increasing Adverse Effects: Increasing adverse effects of the products is expected to hinder the market growth over the forecast period. For instance, according to the data published by the U.S. Food and Drug Administration (FDA) on August 28, 2019, the Food and Drug Administration (FDA) received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure.

Market players should focus on the adverse effects causing due to consumption of the drugs products, and work towards minimizing the adverse effects which aid in the market growth over the forecast period.

Recent Developments:

New product launches:

• On December 7, 2021, Zydus Cadila, a pharmaceutical company based in India, launched a generic version of Gilead Sciences’ Hepatitis C drug Sofosbuvir in India under the brand name ‘SoviHep’.
• On September 24, 2018, Gilead Sciences, Inc., a pharmaceutical company, announced the launch of a generic version of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for hepatitis C treatment.

Acquisition and partnerships:

• On May 31, 2023, The Institute of Drug Technology (Farmanguinhos/Fiocruz) signed a new partnership for the technological transfer of the drug Daclatasvir. This formalization allows expanding access to the drug deemed strategic for the Brazilian Unified Health System (SUS)

Figure 2. Hepatitis C Drugs Market Share (%), By Route of Administration, 2026

To learn more about this report, Download Free Sample

Top Companies in Hepatitis C drugs market:

• Gilead Sciences
• AbbVie
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Hoffmann-La Roche AG
• Boehringer Ingelheim
• Achillion Pharmaceuticals

Definition: Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it.

Few Other Promising Reports in Pharmaceuticals

Hepatitis Drugs Market

Hepatitis Vaccine Market